RU2016133305A3 - - Google Patents

Download PDF

Info

Publication number
RU2016133305A3
RU2016133305A3 RU2016133305A RU2016133305A RU2016133305A3 RU 2016133305 A3 RU2016133305 A3 RU 2016133305A3 RU 2016133305 A RU2016133305 A RU 2016133305A RU 2016133305 A RU2016133305 A RU 2016133305A RU 2016133305 A3 RU2016133305 A3 RU 2016133305A3
Authority
RU
Russia
Application number
RU2016133305A
Other versions
RU2016133305A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/424,000 external-priority patent/US8236857B2/en
Priority claimed from US13/487,348 external-priority patent/US20120244221A1/en
Application filed filed Critical
Publication of RU2016133305A3 publication Critical patent/RU2016133305A3/ru
Publication of RU2016133305A publication Critical patent/RU2016133305A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2016133305A 2012-03-19 2013-03-14 Состав с длительным высвобождением для снижения частоты мочеиспускания и способ его применения RU2016133305A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13/424,000 US8236857B2 (en) 2010-07-08 2012-03-19 Extended-release formulation for reducing the frequency of urination and method of use thereof
US13/424,000 2012-03-19
US13/487,348 2012-06-04
US13/487,348 US20120244221A1 (en) 2010-07-08 2012-06-04 Extended-release formulation for reducing the frequency of urination and method of use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2014142066/15A Division RU2599017C2 (ru) 2012-03-19 2013-03-14 Состав с длительным высвобождением для снижения частоты мочеиспускания и способ его применения

Publications (2)

Publication Number Publication Date
RU2016133305A3 true RU2016133305A3 (ru) 2018-12-10
RU2016133305A RU2016133305A (ru) 2018-12-10

Family

ID=49223209

Family Applications (3)

Application Number Title Priority Date Filing Date
RU2014142025A RU2669565C2 (ru) 2012-03-19 2013-03-13 Препарат длительного высвобождения для снижения частоты мочеиспускания и способ его применения
RU2014142066/15A RU2599017C2 (ru) 2012-03-19 2013-03-14 Состав с длительным высвобождением для снижения частоты мочеиспускания и способ его применения
RU2016133305A RU2016133305A (ru) 2012-03-19 2013-03-14 Состав с длительным высвобождением для снижения частоты мочеиспускания и способ его применения

Family Applications Before (2)

Application Number Title Priority Date Filing Date
RU2014142025A RU2669565C2 (ru) 2012-03-19 2013-03-13 Препарат длительного высвобождения для снижения частоты мочеиспускания и способ его применения
RU2014142066/15A RU2599017C2 (ru) 2012-03-19 2013-03-14 Состав с длительным высвобождением для снижения частоты мочеиспускания и способ его применения

Country Status (15)

Country Link
EP (2) EP2827852A4 (ru)
JP (5) JP2015510928A (ru)
KR (4) KR20140134333A (ru)
CN (4) CN104302284A (ru)
AU (4) AU2013235518B2 (ru)
BR (2) BR112014020271A8 (ru)
CA (2) CA2866853A1 (ru)
HK (3) HK1251469A1 (ru)
MX (3) MX2014011128A (ru)
MY (2) MY174090A (ru)
NZ (6) NZ630471A (ru)
RU (3) RU2669565C2 (ru)
SG (2) SG11201500408VA (ru)
WO (2) WO2013142197A1 (ru)
ZA (2) ZA201405862B (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10596127B2 (en) 2013-03-14 2020-03-24 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
MX2016001030A (es) 2013-07-23 2016-10-07 Allergan Inc Métodos y composiciones que comprenden desmopresina en combinación con un agonista del receptor beta 3-adrenérgico.
CN106714805A (zh) * 2014-06-06 2017-05-24 韦尔斯利医药有限公司 降低排尿频率的药物制剂及其使用方法
KR101809908B1 (ko) * 2014-07-21 2018-01-25 주식회사 종근당 5-알파환원효소억제제를 포함하는 조성물
WO2016081772A1 (en) * 2014-11-20 2016-05-26 Allergan, Inc. Methods and compositions comprising desmopressin in combination with an alpha-adrenergic receptor antagonist
SG11201805530RA (en) * 2015-09-30 2018-07-30 Wellesley Pharmaceuticals Llc Composition for reducing the frequency of urination, method of making and use thereof
AU2016331879A1 (en) * 2015-09-30 2018-05-17 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
CN105238124B (zh) * 2015-11-16 2018-02-09 太仓东能环保设备有限公司 一种抗菌腻子粉
JP6294924B2 (ja) 2016-09-05 2018-03-14 株式会社Ｓｕｂａｒｕ 車両の走行制御装置

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2320193A1 (en) * 1998-02-10 1999-08-19 Welfide Corporation Controlled release preparation
US20020102309A1 (en) * 1999-09-14 2002-08-01 Jane C. I. Hirsh Controlled release formulation for administration of an anti-inflammatory naphthalene derivative
DE10116978A1 (de) * 2001-04-05 2002-10-10 Merck Patent Gmbh Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
KR20050005410A (ko) * 2002-02-19 2005-01-13 파마시아 코포레이션 요실금 치료용으로서의 시클로옥시게나제 저해제 및항무스카린제의 용도
US20060035923A1 (en) * 2002-06-07 2006-02-16 Rian Van Meeteren Overactive bladder treating drug
US20040054008A1 (en) * 2002-09-13 2004-03-18 Tohru Araki Medicament for treatment of nocturia
DE602004003172T2 (de) * 2003-03-21 2007-09-27 Dynogen Pharmaceuticals Inc., Waltham Verfahren zur behandlung von erkrankungen der unteren harnwege mit antimuskarinika und mit modulatoren der alpha-2-delta untereinheit des kalziumkanals
CN1758904A (zh) * 2003-03-21 2006-04-12 麦克内尔-Ppc股份有限公司 非甾体抗炎药物的给药方案
EP1627876A1 (en) * 2004-08-20 2006-02-22 Ferring B.V. Heterocyclic condensed compounds useful as antidiuretic agents
WO2006022420A1 (ja) * 2004-08-25 2006-03-02 Takeda Pharmaceutical Company Limited 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
CA2612508A1 (en) * 2005-06-17 2006-12-28 Dynamis Therapeutics, Inc. Treatment of inflammatory conditions
US20080085314A1 (en) * 2005-07-29 2008-04-10 Shalaby Shalaby W Solid oral formulations for combination therapy
BRPI0615432A2 (pt) * 2005-09-02 2011-05-17 Theravida Inc composição farmacêutica, e, uso de compostos
US20120064159A1 (en) * 2009-05-28 2012-03-15 Aptapharma, Inc. Multilayer Oral Tablets Containing a Non-Steroidal Anti-Inflammatory Drug and/or Acetaminophen
GB201003731D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
US20120010294A1 (en) * 2010-07-08 2012-01-12 Dill David A Compositions and methods for the inhibition of muscle contraction
US20120244221A1 (en) * 2010-07-08 2012-09-27 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof

Also Published As

Publication number Publication date
NZ712594A (en) 2016-09-30
CN107789626A (zh) 2018-03-13
NZ628079A (en) 2016-05-27
EP2827851A4 (en) 2015-10-14
JP2018138602A (ja) 2018-09-06
HK1204553A1 (en) 2015-11-27
BR112014020113A2 (ru) 2017-06-20
RU2014142066A (ru) 2016-05-10
CN107157991A (zh) 2017-09-15
MY175764A (en) 2020-07-08
KR20140134284A (ko) 2014-11-21
WO2013142197A1 (en) 2013-09-26
MX2014011128A (es) 2015-08-10
AU2013235518A1 (en) 2014-09-25
NZ714288A (en) 2016-12-23
RU2669565C2 (ru) 2018-10-12
AU2013235507A1 (en) 2014-08-21
NZ718163A (en) 2017-09-29
BR112014020271A8 (pt) 2017-07-11
AU2017203139A1 (en) 2017-06-01
NZ630471A (en) 2016-04-29
KR20170015537A (ko) 2017-02-08
MX2019008817A (es) 2019-09-26
MY174090A (en) 2020-03-09
AU2017203139B2 (en) 2018-07-19
AU2013235507B2 (en) 2017-03-23
AU2013235518A2 (en) 2014-10-09
SG11201500409SA (en) 2015-03-30
RU2014142025A (ru) 2016-05-10
BR112014020271A2 (ru) 2017-06-20
RU2016133305A (ru) 2018-12-10
ZA201406146B (en) 2016-08-31
RU2599017C2 (ru) 2016-10-10
BR112014020113A8 (pt) 2017-07-11
KR20140134333A (ko) 2014-11-21
JP2016172752A (ja) 2016-09-29
ZA201405862B (en) 2016-08-31
EP2827852A4 (en) 2016-03-02
AU2017203246B2 (en) 2018-10-18
CA2866853A1 (en) 2013-07-26
AU2017203246A1 (en) 2017-06-08
HK1251469A1 (zh) 2019-02-01
JP2018024693A (ja) 2018-02-15
NZ714662A (en) 2016-08-26
CN104302284A (zh) 2015-01-21
MX2014011129A (es) 2015-08-10
EP2827852A1 (en) 2015-01-28
EP2827851A1 (en) 2015-01-28
HK1243921A1 (zh) 2018-07-27
WO2013142274A1 (en) 2013-09-26
JP2015510928A (ja) 2015-04-13
SG11201500408VA (en) 2015-03-30
CA2866755A1 (en) 2013-09-26
AU2013235518B2 (en) 2017-03-02
JP2015510936A (ja) 2015-04-13
CN104321056A (zh) 2015-01-28
KR20190003840A (ko) 2019-01-09

Similar Documents

Publication Publication Date Title
BR112014017635A2 (ru)
BR112014017614A2 (ru)
BR112014017625A2 (ru)
BR112014017659A2 (ru)
BR112014017646A2 (ru)
BR112014017638A2 (ru)
BR112014017607A2 (ru)
BR112014019955A2 (ru)
BR112014017634A2 (ru)
BR112014017609A2 (ru)
BR112014017644A2 (ru)
BR112014017728A2 (ru)
BR112014017647A2 (ru)
BR112014017618A2 (ru)
BR112014017652A2 (ru)
BR112014017621A2 (ru)
BR112014017630A2 (ru)
BR112014017622A2 (ru)
BR112014017627A2 (ru)
BR112014017623A2 (ru)
BR112014018751A2 (ru)
BR112014017641A2 (ru)
BR112014020271A2 (ru)
BR112014017631A2 (ru)
BR112014017636A2 (ru)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20200207